ATE542829T1 - Impfstoff - Google Patents

Impfstoff

Info

Publication number
ATE542829T1
ATE542829T1 AT02751380T AT02751380T ATE542829T1 AT E542829 T1 ATE542829 T1 AT E542829T1 AT 02751380 T AT02751380 T AT 02751380T AT 02751380 T AT02751380 T AT 02751380T AT E542829 T1 ATE542829 T1 AT E542829T1
Authority
AT
Austria
Prior art keywords
antigens
antigenic polypeptides
vaccine
vaccines
expressed
Prior art date
Application number
AT02751380T
Other languages
English (en)
Inventor
S Foster
James Mond
S Clarke
P Mcdowell
K Brummel
Original Assignee
Univ Sheffield
Biosynexus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0118825A external-priority patent/GB0118825D0/en
Priority claimed from GB0200349A external-priority patent/GB0200349D0/en
Application filed by Univ Sheffield, Biosynexus Inc filed Critical Univ Sheffield
Application granted granted Critical
Publication of ATE542829T1 publication Critical patent/ATE542829T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT02751380T 2001-08-02 2002-08-02 Impfstoff ATE542829T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0118825A GB0118825D0 (en) 2001-08-02 2001-08-02 Antigenic polypeptides
GB0200349A GB0200349D0 (en) 2002-01-09 2002-01-09 Antigenic polypeptides
PCT/GB2002/003606 WO2003011899A2 (en) 2001-08-02 2002-08-02 Antigenic polypeptides

Publications (1)

Publication Number Publication Date
ATE542829T1 true ATE542829T1 (de) 2012-02-15

Family

ID=26246393

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02751380T ATE542829T1 (de) 2001-08-02 2002-08-02 Impfstoff

Country Status (7)

Country Link
US (2) US7410647B2 (de)
EP (1) EP1412379B1 (de)
JP (1) JP4404627B2 (de)
AT (1) ATE542829T1 (de)
AU (1) AU2002355677A1 (de)
CA (2) CA2808598A1 (de)
WO (1) WO2003011899A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
US7628994B2 (en) 2003-03-31 2009-12-08 Intercell Ag S. epidermidis antigens
CN1980692A (zh) * 2003-07-24 2007-06-13 麦克公司 用于诱导针对金黄色葡萄球菌的保护性免疫反应的多肽
CA2555342A1 (en) 2004-02-18 2005-09-01 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
FR2871237B1 (fr) * 2004-06-08 2011-03-11 Abag Nouveaux polypeptides pour la mise en evidence in vitro et la prevention des infections staphylococciques sur protheses articulaires et autres materiels etrangers implantes
FR2871159A1 (fr) * 2004-06-08 2005-12-09 Abag Sa Nouvelles proteines permettant, notamment, la mise en evidence in vitro et la prevention des infections a staphylocoques a coagulase negative
JP2008513406A (ja) 2004-09-22 2008-05-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
EP2340848A3 (de) 2004-10-21 2011-09-14 Wyeth LLC Immunogene Zusammensetzungen von Staphylococcus epidermidis Polypeptide und Polynucleotide Antigenen
EP1812066A4 (de) * 2004-10-25 2010-06-30 Univ Western Ontario Auf isd-protein aus staphylococcus aureus basierende antiinfektionsmittel
MY148405A (en) 2006-03-30 2013-04-30 Glaxosmithkline Biolog Sa Immunogenic composition
GB0610776D0 (en) * 2006-05-31 2006-07-12 Univ Bath Novel applications for staphylococcus aureus Sbi protein
EP2374466B1 (de) * 2007-05-04 2013-08-28 Krönke, Martin Impfstoff zum Schutz gegen staphylococcus aureus auf der Basis zellwandassoziierter Proteine
KR20100072228A (ko) 2007-08-31 2010-06-30 유니버시티 오브 시카고 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
PT2268618E (pt) 2008-03-03 2015-10-12 Novartis Ag Compostos e composições moduladores da actividade tlr
US8758765B2 (en) 2008-07-29 2014-06-24 The University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
US8101190B2 (en) * 2009-03-03 2012-01-24 Ingen Biosciences Method for diagnosing staphylococcal infections
JP5789250B2 (ja) 2009-04-03 2015-10-07 ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago プロテインA(SpA)変種に関連する組成物および方法
AU2010258677B2 (en) 2009-06-10 2016-10-06 Glaxosmithkline Biologicals S.A. Benzonaphthyridine-containing vaccines
JP5395264B2 (ja) 2009-06-22 2014-01-22 ワイス・エルエルシー 黄色ブドウ球菌(staphylococcusaureus)抗原の免疫原性組成物
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為tlr活性調節劑之化合物及組合物
JP5988492B2 (ja) 2009-09-02 2016-09-07 ノバルティス アーゲー Tlr活性モジュレーターを含む免疫原性組成物
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
WO2011084549A1 (en) 2009-12-15 2011-07-14 Novartis Ag Homogeneous suspension of immunopotentiating compounds and uses thereof
EA031379B1 (ru) 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
CA2803298C (en) 2010-07-02 2020-07-14 The University Of Chicago Compositions and methods related to protein a (spa) variants
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
WO2013066733A1 (en) * 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Protective vaccine based on staphylococcus aureus sa2074 protein
WO2013066731A2 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Protective vaccine based on staphylococcus aureus sa2451 protein
NZ702285A (en) 2012-04-26 2016-07-29 Univ Chicago Staphylococcal coagulase antigens and methods of their use
WO2014011645A1 (en) 2012-07-10 2014-01-16 Merck Sharp & Dohme Corp. Protective vaccine based on staphylococcus aureus sa2493 protein
WO2014013375A1 (en) 2012-07-16 2014-01-23 Pfizer Inc. Saccharides and uses thereof
ES2670863T3 (es) 2013-02-01 2018-06-01 Glaxosmithkline Biologicals Sa Administración intradérmica de composiciones inmunológicas que comprenden agonistas del receptor de tipo Toll
US11458151B2 (en) 2018-02-12 2022-10-04 Inimmune Corporation Toll-like receptor ligands
JP2023547677A (ja) 2020-11-04 2023-11-13 エリゴ・バイオサイエンス キューティバクテリウム・アクネス組換えファージ、その産生方法及び使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4425330A (en) * 1981-05-20 1984-01-10 Cornell Research Foundation, Inc. Bovine mastitis vaccine and method for detecting efficacy thereof
GB8905857D0 (en) * 1989-03-14 1989-04-26 Hoffmann La Roche Plasmodium merozoite rhoptries antigen
US6086896A (en) * 1990-07-16 2000-07-11 Imclone Systems Incorporated Antigenic iron repressible protein from N. meningitidis related to the hemolysin family of toxins
US6008341A (en) * 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
US5807978A (en) * 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
GB9806762D0 (en) 1998-03-31 1998-05-27 Neutec Pharma Plc Treatment and diagnosis of staphylococcal infections
GB0014907D0 (en) * 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
MXPA03011701A (es) 2001-06-15 2004-12-06 Nhibitex Inc Anticuerpos monoclonales y policlonales de reaccion que reconocen las proteinas de superficie a partir de estafilococos coagulasa-negativos y staphylococcus aureus.

Also Published As

Publication number Publication date
US20050256299A1 (en) 2005-11-17
JP4404627B2 (ja) 2010-01-27
US20090269349A1 (en) 2009-10-29
US7410647B2 (en) 2008-08-12
EP1412379A2 (de) 2004-04-28
WO2003011899A2 (en) 2003-02-13
JP2004536885A (ja) 2004-12-09
CA2453937C (en) 2013-05-14
CA2453937A1 (en) 2003-02-13
CA2808598A1 (en) 2003-02-13
AU2002355677A1 (en) 2003-02-17
WO2003011899A3 (en) 2004-02-26
EP1412379B1 (de) 2012-01-25

Similar Documents

Publication Publication Date Title
ATE542829T1 (de) Impfstoff
NO20025838L (no) Antigeniske polypeptider
NO20033364L (no) Fremgangsmåte for identifikasjon, isolasjon og produksjon av antigener tilet spesifikt patogen
PT1409692E (pt) Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina
BR0206565A (pt) Arranjo de antìgeno molecular
IS7133A (is) Afleiða beta-amyloid - T-frumu-mótefnavísisbóluefni
ATE384793T1 (de) Chlamydia antigene und entsprechende dna- fragmente und ihre verwendungen
AP2003002734A0 (en) Purification of HBV antigens for use in vaccines.
DK1259259T3 (da) Mucosal adjuvansformulering
ATE370745T1 (de) Verbesserte polysaccharid- und glykokonjugat- vakzine
CY1111521T1 (el) Λοιμογονος συστηματικος καλυκοϊος αιλουροειδων
IL144265A0 (en) Use of antibodies for the vaccination against cancer
DE60222296D1 (de) Impfstoff von umhüllten viren und verfahren zu seiner herstellung
ES2502366T3 (es) Inducción de inmunidad tumoral por variantes de proteína de unión a folato
GB0409559D0 (en) Polypeptide
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
ECSP034474A (es) Nuevo tratamiento
AU2003294192A8 (en) Inclusion bodies as antigens for the oral vaccination of animals
DE59704477D1 (de) Pharmazeutische antigen-/antikörperpräparation